$0.66
2.59% today
Nasdaq, Dec 02, 07:18 pm CET
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Stock price

$0.68
-0.07 9.24% 1M
-0.02 3.00% 6M
-0.32 32.10% YTD
-0.72 51.50% 1Y
-0.67 49.70% 3Y
-16.80 96.12% 5Y
-385.72 99.82% 10Y
-479.32 99.86% 20Y
Nasdaq, Closing price Mon, Dec 01 2025
-0.03 4.62%
ISIN
US4525EP1011
Symbol
IMUX
Industry

Key metrics

Basic
Market capitalization
$81.7m
Enterprise Value
$46.5m
Net debt
positive
Cash
$35.1m
Shares outstanding
98.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
7.8
Financial Health
Equity Ratio
45.1%
Return on Equity
-545.4%
ROCE
-993.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-105.4m | -
EBIT
$-105.5m | $-103.3m
Net Income
$-103.1m | $-73.6m
Free Cash Flow
$-89.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-10.1% | -
EBIT
-10.2% | -5.4%
Net Income
-6.3% | 26.8%
Free Cash Flow
-17.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.9
Short interest
4.8%
Employees
90
Rev per Employee
$0.0
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Immunic, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Immunic, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
16% 16%
-
- Research and Development Expense 85 85
9% 9%
-
-105 -105
10% 10%
-
- Depreciation and Amortization 0.16 0.16
33% 33%
-
EBIT (Operating Income) EBIT -106 -106
10% 10%
-
Net Profit -103 -103
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Neutral
PRNewsWire
6 days ago
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healt...
Positive
Proactive Investors
17 days ago
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's third quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium. Dr Vitt noted the company had a strong presence at the 2025 ECTRIMS conference, presenting important new data from several clinical studies.
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 90
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today